ARTH Stock Overview
Operates as a biotechnology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Arch Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.21 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$0.17 |
| Beta | 3.47 |
| 1 Month Change | 2.60% |
| 3 Month Change | -19.88% |
| 1 Year Change | -97.51% |
| 3 Year Change | -98.99% |
| 5 Year Change | -99.55% |
| Change since IPO | -99.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARTH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 4.1% | -1.1% | -2.2% |
| 1Y | -97.5% | 10.1% | 23.9% |
Return vs Industry: ARTH underperformed the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: ARTH underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| ARTH volatility | |
|---|---|
| ARTH Average Weekly Movement | 46.8% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARTH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ARTH's weekly volatility has increased from 32% to 47% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 8 | Terrence Norchi | www.archtherapeutics.com |
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company’s flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds.
Arch Therapeutics, Inc. Fundamentals Summary
| ARTH fundamental statistics | |
|---|---|
| Market cap | US$1.14m |
| Earnings (TTM) | -US$12.99m |
| Revenue (TTM) | US$148.16k |
6.2x
P/S Ratio-0.1x
P/E RatioIs ARTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARTH income statement (TTM) | |
|---|---|
| Revenue | US$148.16k |
| Cost of Revenue | US$89.52k |
| Gross Profit | US$58.64k |
| Other Expenses | US$13.05m |
| Earnings | -US$12.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.92 |
| Gross Margin | 39.58% |
| Net Profit Margin | -8,769.17% |
| Debt/Equity Ratio | -74.7% |
How did ARTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 18:05 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arch Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Michael Higgins | Ladenburg Thalmann & Company |
| Raghuram Selvaraju | Rodman & Renshaw, LLC |